This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/guide-to-pharmacology/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/chemspider/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/pharmgkb/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/kegg-compound/
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/pubchem-compound/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/iuphar/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00179/identifier/drugbank/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00179
rdf:type
n4:Drug
n4:description
A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
n4:group
approved
n4:indication
Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).
n4:manufacturer
n20:271B52A3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00179 n24:DB00179
dcterms:title
Masoprocol
adms:identifier
n11:Masoprocol n12:PA164746493 n13:71398 n14:46508042 n17:C10719 n18:22372 n19:4265 n21:4265 n22:64490 n23:DB00179
n4:mechanismOfAction
Although the exact mechanism of action is not known, studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known.
n4:synonym
Meso-ndga Nordihydroguaiaretic acid Meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol) Meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol Masoprocolum CHX 100 Meso-beta,gamma-dimethyl-alpha,delta-bis(3,4-dihydroxyphenyl)butan Actinex erythro-Nordihydroguaiaretic acid Meso-nordihydroguaiaretic acid Meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol Meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane NDGA Meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane CHX-100
n4:toxicity
Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.
n6:hasConcept
n7:M0329970
n4:IUPAC-Name
n5:271B52A8-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B52AE-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B52AD-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B52AA-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B52AB-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B52AC-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B52A6-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B52A7-363D-11E5-9242-09173F13E4C5 n5:271B52A4-363D-11E5-9242-09173F13E4C5 n5:271B52BF-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B52A5-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:L01XX10
n4:H-Bond-Acceptor-Count
n5:271B52B4-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B52B5-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B52AF-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B52B0-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B52B2-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B52B1-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B52B3-363D-11E5-9242-09173F13E4C5
n4:absorption
Less than 1%-2% is absorbed through the skin over a 4-day period following application.
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
500-38-9
n4:category
n4:Bioavailability
n5:271B52BA-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B52BC-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B52BD-363D-11E5-9242-09173F13E4C5
n4:Melting-Point
n5:271B52BE-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B52B9-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B52B8-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B52BB-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B52A9-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B52B6-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B52B7-363D-11E5-9242-09173F13E4C5